1 / 12

The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum

The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum. Pharmaceutical Compliance Case Study. James G. Sheehan Associate U.S. Attorney 215-861-8301 Jim.Sheehan@usdoj.gov. DISCLAIMERS. MY OPINIONS- BUT NOT OFFICIAL POLICY OF DEPARTMENT OF JUSTICE

dirk
Télécharger la présentation

The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Pharmaceutical Compliance Case Study James G. Sheehan Associate U.S. Attorney 215-861-8301 Jim.Sheehan@usdoj.gov

  2. DISCLAIMERS • MY OPINIONS- BUT NOT OFFICIAL POLICY OF DEPARTMENT OF JUSTICE • COMPLAINT OR INDICTMENT CONTAINS ALLEGATIONS-DEFENDANT HAS RIGHT TO PUT THE GOVERNMENT TO ITS PROOF AT TRIAL • LIMITED IN WHAT I CAN SAY ABOUT PENDING CASES

  3. FDA approves SwarthmorePharma’s new antidepressant, Viaxal for an indication of depression. Clinical studies show Viaxal matched the success of the most effective SSRIs but avoided the well-known sexual side effects of the SSRI class in both men and women.

  4. Aggressive direct-to-consumer marketing program promoted Viaxal as a treatment for depression, and mentioned the research showing reduced effects on libido. FDA warning letter. Advertisements back pages of USA Today’s sports section offering internet sales of Viaxal Passengers on cruise ships met by hawkers in pharmacists’ jackets offering Viaxal without a prescription.

  5. Dr. Timothy Cleary’s bestseller, Viaxal Boomers SwarthmorePharma had no formal company relationship with Dr. Cleary Vboom! Website, t-shirts, mugs, greeting cards, bumper stickers. Sales of over $4 billion annually.

  6. Anecdotal reports of hyperactivity, agitation, aggressive behavior, and suicide related to use of the drug by some patients. (many of the leading SSRIs had similar anecdotal reports). Two researchers with the Australian medicines regulatory authority became concerned, and began reviewing previous studies and doing retrospective studies to determine the existence and extent of these problems.Their negative article has been submitted to the New England Journal of Medicine.

  7. Six months ago a scientist who had worked with the CRO, CroData contacts the Wall Street Journal, alleging that the CRO engaged by SwarthmorePharma had suppressed and manipulated Viaxal data. Two weeks ago, the Journal printed a story, on the second page of the business section. CroData and SwarthmorePharma could not be reached for comment.

  8. Last week, the US Attorneys’ Office in Miami served an Authorized Investigative Demand(AID) on the offices of SwarthmorePharma AID served on CroData same day .

  9. CAROLYN MCELROY, ESQUIREMintz Levin Cohn Ferris Glovsky & Popeo701 Pennsylvania AvenueWashington, DC 20004202-434-7408

  10. DAVIA B. TEMIN, PRESIDENTTemin and Company136 E. 57th StreetSuite 1700New York, NY 10022212-588-8788

  11. SIX MONTHS LATER . . .

  12. ONE YEAR LATER . . .

More Related